Skip to Main Content
Try STAT+ TODAY
Trending:
Health
STAT+
Biotech
First Opinion
The Readout

Celgene’s having a year & a word on the other kind of biobucks

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Feb. 28, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for February 28, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

If AI invents a new medicine, who gets the…
If AI invents a new medicine, who gets the patent?
How Tennessee is creating new opportunities for doctors trained…
How Tennessee is creating new opportunities for doctors trained outside the U.S.
See how much Covid-19 relief money health care providers…
See how much Covid-19 relief money health care providers in your state got
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories